title: Imatinib may be useful in the management of patients with glioblastoma.
authors.forename: Cem
authors.initials: C
authors.lastname: Boruban
authors.forename: Ozlem
authors.initials: O
authors.lastname: Yavas
authors.forename: Ozden
authors.initials: O
authors.lastname: Altundag
authors.forename: Muzaffer B
authors.initials: MB
authors.lastname: Altundag
authors.forename: Kadri
authors.initials: K
authors.lastname: Altundag
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D001927:Brain Diseases / Q000532:radiotherapy*; D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D005909:Glioblastoma / Q000532:radiotherapy*; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D011838:Radiation-Sensitizing Agents; D000068877:Imatinib Mesylate